secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001140361-24-028194
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore converts TEBE-AM to registrational Phase 3 evaluating KIMMTRAK for cutaneous melanoma
--------------------------------------------------------------------------------

- Trial converted to Phase 3 registrational after FDA consultation; three arms: KIMMTRAK monotherapy, KIMMTRAK+pembrolizumab, control.
- All patients randomized from trial start included in Phase 3 intent-to-treat population; time to final OS analysis expected to accelerate.
- Phase 3 to test KIMMTRAK in previously treated advanced cutaneous melanoma; rapid accrual made Phase 2 OS maturity timeline moot.
- Phase 1b data showed ~75% one-year OS rate for KIMMTRAK+checkpoint combo in metastatic cutaneous melanoma patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124028194/0001140361-24-028194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124028194/ef20030315_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-028194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer